Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA)

被引：1
|
作者：
Ludwig, H. [1 ]
Crawford, J. [2 ]
Osterborg, A. [3 ]
Fleishman, A. [4 ]
Lillie, T. [4 ]
Sueto, T. [5 ]
Glaspy, J. [6 ]
机构：
[1] Wilhelminespital, Dept Med Oncol, Vienna, Austria
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] Amgen Inc, Thousand Oaks, CA USA
[5] Amgen GmbH, Int Med Affairs, Zug, Switzerland
[6] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70623-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1104
引用
收藏
页码：142 / 143
页数：2
相关论文
共 50 条
  • [1] Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia
    Ludwig, Heinz
    Crawford, Jeffrey
    Osterborg, Anders
    Vansteenkiste, Johan
    Henry, David H.
    Fleishman, Alex
    Bridges, Ken
    Glaspy, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2838 - 2847
  • [2] Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA):: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)
    Glaspy, J.
    Osterborg, A.
    Ludwig, H.
    Fleishman, A.
    Lillie, T.
    Suto, T.
    Crawford, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 147 - 148
  • [3] The effect of hemoglobin (Hb) level at ESA initiation on outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): A patient-based meta-analysis from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)
    Crawford, J.
    Henry, D.
    Vansteenkiste, J.
    Ludwig, H.
    Lillie, T.
    Fleishman, A.
    Glaspy, J.
    BLOOD, 2007, 110 (11) : 12B - 12B
  • [4] Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia
    Taylor, K
    Ganly, P
    Charu, V
    DiBenedetto, J
    Kracht, K
    Rossi, G
    Hernandez, E
    BLOOD, 2005, 106 (11) : 992A - 993A
  • [5] Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized double-blind placebo-controlled trails
    Hedenus, M
    Vansteenkiste, J
    Kotasek, P
    Austin, M
    Amado, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6941 - 6948
  • [6] Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
    Hernandez, Enrique
    Ganly, Peter
    Charu, Veena
    DiBenedetto, Joseph
    Tomita, Dianne
    Lillie, Tom
    Taylor, Kerry
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (09) : 2109 - 2120
  • [7] Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials
    Ohashi, Yasuo
    Uemura, Yukari
    Fujisaka, Yasuhito
    Sugiyama, Toru
    Ohmatsu, Hironobu
    Katsumata, Noriyuki
    Okamoto, Rumiko
    Saijo, Nagahiro
    Hotta, Tomomitsu
    CANCER SCIENCE, 2013, 104 (04) : 481 - 485
  • [8] Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials
    Dennis A. Revicki
    Donald Stull
    Margaret Vernon
    Michael Rader
    Dianne Tomita
    Hema N. Viswanathan
    Quality of Life Research, 2012, 21 : 311 - 321
  • [9] Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials
    Revicki, Dennis A.
    Stull, Donald
    Vernon, Margaret
    Rader, Michael
    Tomita, Dianne
    Viswanathan, Hema N.
    QUALITY OF LIFE RESEARCH, 2012, 21 (02) : 311 - 321
  • [10] RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF DARBEPOETIN ALFA (DA) ADMINISTERED EVERY THREE WEEKS (Q3W) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)
    Suzuki, Y.
    Tokuda, Y.
    Okamoto, R.
    Nakagawa, K.
    Ando, K.
    Iwata, H.
    Tobinai, K.
    Tanigawara, Y.
    Hotta, T.
    Saijo, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 277 - 277
12345